Tsilimigras Diamantis I, Lu Pamela, Tsai Susan, Pawlik Timothy M, Konda Bhavana, Patel Dipen, Sukrithan Vineeth, Cloyd Jordan M
Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Department of Medicine, Division of Medical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Ann Surg Oncol. 2025 Aug 5. doi: 10.1245/s10434-025-17982-7.
Current guidelines are conflicting as to whether mesoappendiceal invasion (MAI) among patients with appendiceal neuroendocrine tumors (aNETs) warrants right hemicolectomy (RHC), especially in the absence of other concomitant high-risk features.
Patients who underwent resection of aNETs were identified in the National Cancer Database. Patients with pT3 aNETs (i.e. size > 4 cm or MAI/subserosal invasion [SI]+) were further stratified as pT3a (size ≤ 4 cm, + MAI/SI) or pT3b (size > 4 cm, ± MAI/SI). The association of MAI/SI with nodal metastasis (pN+) relative to the presence/absence of other risk factors was examined. The prognostic impact of the extent of resection (i.e. RHC vs. appendectomy) among patients with MAI/SI was assessed.
Among 4819 patients who underwent resection for aNETs, 1662 had pT3 tumors, of which 1309 (78.7%) were pT3a and 353 (21.3%) were pT3b. The overall incidence of pN+ disease was 7.5%, and varied by American Joint Committee on Cancer (AJCC) pT stage (pT1: 0.9%; pT2: 9.2%; pT3: 8.5%; pT4: 29.8%; p < 0.001). pT3a stage was less frequently associated with pN+ disease compared with pT3b disease (6.8% vs. 14.7%; p = 0.02). In the absence of other established risk factors, the presence of MAI/SI alone was associated with a low probability of pN+ (3.4%). The 3-year overall survival among patients with pT3a aNETs was comparable following RHC versus simple appendectomy (92.7% vs. 95.2%; p = 0.43).
Among patients with resected aNETs, MAI/SI alone in the absence of other established risk factors was associated with a low likelihood of nodal metastasis and equivalent long-term outcomes regardless of the extent of surgical resection. The presence of MAI/SI alone should not be an indication for RHC.
目前的指南对于阑尾神经内分泌肿瘤(aNETs)患者的阑尾系膜侵犯(MAI)是否需要行右半结肠切除术(RHC)存在冲突,尤其是在没有其他伴随高危特征的情况下。
在国家癌症数据库中识别接受aNETs切除术的患者。pT3期aNETs患者(即肿瘤大小>4 cm或存在MAI/浆膜下侵犯[SI]+)进一步分层为pT3a(肿瘤大小≤4 cm,存在MAI/SI)或pT3b(肿瘤大小>4 cm,存在或不存在MAI/SI)。相对于其他危险因素的存在与否,研究MAI/SI与淋巴结转移(pN+)的相关性。评估MAI/SI患者中手术切除范围(即RHC与阑尾切除术)对预后的影响。
在4819例接受aNETs切除术的患者中,1662例为pT3期肿瘤,其中1309例(78.7%)为pT3a期,353例(21.3%)为pT3b期。pN+疾病的总体发生率为7.5%,并因美国癌症联合委员会(AJCC)pT分期而异(pT1:0.9%;pT2:9.2%;pT3:8.5%;pT4:29.8%;p<0.001)。与pT3b期疾病相比,pT3a期与pN+疾病的相关性较低(6.8%对14.7%;p=0.02)。在没有其他既定危险因素的情况下,单独存在MAI/SI与pN+的低概率相关(3.4%)。pT3a期aNETs患者行RHC与单纯阑尾切除术后的3年总生存率相当(92.7%对95.2%;p=0.43)。
在接受aNETs切除术的患者中,在没有其他既定危险因素的情况下,单独存在MAI/SI与淋巴结转移的低可能性相关,并且无论手术切除范围如何,长期预后相当。单独存在MAI/SI不应作为RHC的指征。